Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

161. Inflammation-Based Prognostic Score Predicts Postoperative Survival of Patients with Interstitial Pneumonia After Undergoing Lung Cancer Resection

Inflammation-Based Prognostic Score Predicts Postoperative Survival of Patients with Interstitial Pneumonia After Undergoing Lung Cancer Resection 29344688 2018 01 18 1432-2323 2018 Jan 17 World journal of surgery World J Surg Inflammation-Based Prognostic Score Predicts Postoperative Survival of Patients with Interstitial Pneumonia After Undergoing Lung Cancer Resection. 10.1007/s00268-017-4426-4 Idiopathic interstitial pneumonias (IIPs) are associated with an increased risk of lung cancer (...) . Glasgow prognostic score (GPS), which uses serum C-reactive protein (CRP) and albumin levels to indicate systemic inflammatory response and nutrition level, has been reported to be a predictor of overall survival in patients with various types of cancer. We evaluated the usefulness of GPS for prediction of survival of patients with both lung cancer and IIPs following a lung resection procedure. Patients with IIPs who underwent lung cancer resection from January 2006 through December 2015 were

EvidenceUpdates2018

162. ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) - Du - 2018 - Thoracic Cancer - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due to technical difficulties. INVITED REVIEW Open Access ALK‐ rearrangement in non‐small‐cell lung cancer (NSCLC) Department (...) of Pathology, Cancer Center of People's Liberation Army of China, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China These authors contributed equally to this work and should be considered co‐first authors. Department of Pathology, Cancer Center of People's Liberation Army of China, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China These authors contributed equally to this work and should be considered co‐first authors. Department of Lung Cancer, Cancer

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

163. Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non‐small cell lung cancer patients after surgery

Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non‐small cell lung cancer patients after surgery Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non‐small cell lung cancer patients after surgery - Lin - 2018 - Thoracic Cancer - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org (...) is unavailable due to technical difficulties. ORIGINAL ARTICLE Open Access Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non‐small cell lung cancer patients after surgery Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China Corresponding Author E-mail address: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China Correspondence Guowei Che, Department of Thoracic Surgery, West China Hospital, Sichuan

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

164. Expression and copy number gains of the RET gene in 631 early and mid stage non‐small cell lung cancer cases

Expression and copy number gains of the RET gene in 631 early and mid stage non‐small cell lung cancer cases Expression and copy number gains of the RET gene in 631 early and mid stage non‐small cell lung cancer cases - Tan - 2018 - Thoracic Cancer - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due to technical difficulties (...) . ORIGINAL ARTICLE Open Access Expression and copy number gains of the RET gene in 631 early and mid stage non‐small cell lung cancer cases Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, China Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, China Cancer Research Institute, Central South University, Changsha, China Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

165. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations 1 Oizumi S, et al. ESMO Open 2018;3:e000313. doi:10.1136/esmoopen-2017-000313 Open Access Updated survival outcomes of NEJ005/ TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small (...) cell lung cancer with sensitive EGFR mutations Satoshi Oizumi, 1,2 Shunichi Sugawara, 3 Koichi Minato, 4 Toshiyuki Harada, 5 Akira Inoue, 6 Yuka Fujita, 7 Makoto Maemondo, 8 Satoshi Watanabe, 9 Kazuhiko Ito, 10 Akihiko Gemma, 11 Yoshiki Demura, 12 Shinichi Fukumoto, 1 Hiroshi Isobe, 13 Ichiro Kinoshita, 14 Satoshi Morita, 15 Kunihiko Kobayashi, 16 Koichi Hagiwara, 17 Keisuke Aiba, 18 Toshihiro Nukiwa, 19 on behalf of North East Japan Study Group and Tokyo Cooperative Oncology Group Original

ESMO open2018 Full Text: Link to full Text with Trip Pro

166. Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor

Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor 29556515 2018 11 14 2331-4737 5 1-2 2018 Jan Oncoscience Oncoscience Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. 21-38 10.18632/oncoscience.395 EGFR-based targeted therapies have shown limited success in smokers. Identification (...) of alternate signaling mechanism(s) leading to TKI resistance in smokers is critically important. We observed increased resistance to erlotinib in H358 NSCLC (non-small cell lung carcinoma) cells chronically exposed to cigarette smoke (H358-S) compared to parental cells. SILAC-based mass-spectrometry approach was used to study altered signaling in H358-S cell line. Importantly, among the top phosphosites in H358-S cells we observed hyperphosphorylation of EGFR (Y1197) and non-receptor tyrosine kinase FAK

Oncoscience2018 Full Text: Link to full Text with Trip Pro

167. Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients Real-life experience of ceritinib in crizotinib-pretreated ALK + advanced non- small cell lung cancer patients Jacques Cadranel 1 , Alexis B. Cortot 2 , Hervé Lena 3 , Bertrand Mennecier 4 , Pascal Do 5 , Eric Dansin 6 , Julien Mazieres 7 , Christos Chouaid 8 , Maurice Perol 9 , Fabrice Barlesi 10 , Gilles Robinet 11 , Sylvie Friard 12 , Luc Thiberville 13 , Clarisse Audigier-Valette 14 (...) , Alain Vergnenegre 15 , Virginie Westeel 16 , Khemaies Slimane 17 , Alexandru Buturuga 17 , Denis Moro-Sibilot 18 and Benjamin Besse 19,20 ABSTRACT Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK + ) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced ALK + or ROS proto- oncogene 1 positive (ROS1 + ) tumours

ERJ open research2018 Full Text: Link to full Text with Trip Pro

168. Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy Redirecting

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

169. MAGE‐A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer

MAGE‐A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer ORIGINAL ARTICLE MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer Lina Gu 1 , Meixiang Sang 1,2 , Danjing Yin 1 , Fei Liu 1 , Yunyan Wu 1 , Shina Liu 1 , Weina Huang 1 & Baoen Shan 1,2 1 Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China 2 Tumor Research Institute, The Fourth Hospital of Hebei (...) Medical University, Shijiazhuang, China Keywords Biological marker; lung cancer; MAGE; metastasis; prognosis. Correspondence Baoen Shan, Research Center, The Fourth Hospital of Hebei Medical University, 14 Jiankang Road, Shijiazhuang, Hebei 050017, China. Tel: +86 311 8609 5283 Fax: +86 311 8699 2004 Email: baoenshan@hotmail.com Received: 29 September 2017; Accepted: 6 November 2017. doi: 10.1111/1759-7714.12571 Thoracic Cancer 9 (2018) 431–438 Abstract Background: MAGE-A genes belong to the cancer

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

170. WITHDRAWN: Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission.

WITHDRAWN: Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. BACKGROUND: Prophylactic cranial irradiation halves the rate of brain metastases in patients with small cell lung cancer. Individual randomized trials conducted on patients in complete remission were unable to clarify whether this treatment improves survival. OBJECTIVES: This study aims to test whether prophylactic cranial irradiation prolongs survival of patients (...) with small cell lung cancer in complete remission. SEARCH METHODS: Published and unpublished trials were eligible. Electronic databases (Medline, Cancerlit, Excerpta Medica, Biosis from 1965 to 1998), reference lists of trial publications, review articles and relevant books were used to identify potentially eligible trials. The search was also guided by discussions with investigators and experts, and the examination of meeting proceedings and of the Physician Data Query clinical trial registry. SELECTION

Cochrane2018

171. Treatment outcome for locally advanced non‐small‐cell lung cancer using TomoDirect plan and its characteristics compared to the TomoHelical plan

Treatment outcome for locally advanced non‐small‐cell lung cancer using TomoDirect plan and its characteristics compared to the TomoHelical plan ORIGINAL ARTICLE Treatment outcome for locally advanced non-small-cell lung cancer using TomoDirect plan and its characteristics compared to the TomoHelical plan Yuki Mukai, MD, 1 Motoko Omura, MD, 2 Harumitu Hashimoto, BS, 3 Kengo Matsui, MD, 2 Hideyuki Hongo, MS, 2 Wataru Yamakabe, TA, 2 Miwa Yoshida, TA, 2 Masaharu Hata, MD, 1 & Tomio Inoue, MD (...) of the TD plan for locally advanced non-small-cell lung cancer (NSCLC) and (2) to compare the characteristics of TD plans with those of TH plans. Methods: Twenty-one patients with NSCLC were treated using the TD system. The prescribed dose was 40 Gy/20 Fx for the initial planning target volume (PTV), which included the gross tumour volume (GTV) and lymph node regions. A boost plan of 20 Gy/10 Fx was then applied, focusing on the GTV. For the planning study, matched TH plans of 40 Gy for the initial PTV

Journal of medical radiation sciences2018 Full Text: Link to full Text with Trip Pro

172. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis

Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis Eisuke Kato 1 , Noboru Takayanagi 1 , Yotaro Takaku 1 , Naho Kagiyama 1 , Tetsu Kanauchi 2 , Takashi Ishiguro 1 and Yutaka Sugita 1 Affiliations: 1 Dept of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan. 2 Dept of Radiology, Saitama Cardiovascular and Respiratory Center (...) , Saitama, Japan. Correspondence: Eisuke Kato, Dept of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, 1696 Itai, Kumagaya, Saitama 360-0105, Japan. E-mail: eisuke.kato@med.showa-u.ac.jp ABSTRACT The incidence and risk factors of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) have been poorly investigated. We conducted a retrospective study of 632 patients with IPF to assess the incidence and risk factors of lung cancer development. Seventy patients developed lung

ERJ open research2018 Full Text: Link to full Text with Trip Pro

175. Automated Information Extraction on Treatment and Prognosis for Non–Small Cell Lung Cancer Radiotherapy Patients: Clinical Study

Automated Information Extraction on Treatment and Prognosis for Non–Small Cell Lung Cancer Radiotherapy Patients: Clinical Study JMI-Automated Information Extraction on Treatment and Prognosis for Non–Small Cell Lung Cancer Radiotherapy Patients: Clinical Study | Zheng | JMIR Medical Informatics Sorry, you need to enable javascript for this page to function properly. Menu Search User Sign Up Follow Us on Twitter Browse Journal Browse By Year Browse by Year: Other Journals Want to publish (...) vocabularies [ ]. MedEx aims to extract medication-related information such as dosage and duration [ ]. The Clinical Language Annotation, Modeling, and Processing toolkit integrates award-winning algorithms and, moreover, enables users to customize natural language processing components so as to encode clinical text automatically [ , ]. Medical text extraction processes pathology reports and uses rule-based methods to classify lung cancer stages [ ]. A recent study also demonstrated that the metastatic

JMIR medical informatics2018 Full Text: Link to full Text with Trip Pro

176. [Osimertinib (lung cancer) - addendum to commission A17-20]

[Osimertinib (lung cancer) - addendum to commission A17-20] Osimertinib (nicht kleinzelliges Lungenkarzinom): addendum zum auftrag A17-20; auftrag A17-47 [Osimertinib (lung cancer) - addendum to commission A17-20] Osimertinib (nicht kleinzelliges Lungenkarzinom): addendum zum auftrag A17-20; auftrag A17-47 [Osimertinib (lung cancer) - addendum to commission A17-20] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Osimertinib (nicht kleinzelliges Lungenkarzinom): addendum zum auftrag A17-20; auftrag A17-47. [Osimertinib (lung cancer) - addendum to commission A17-20] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 544. 2017 Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2018

177. [Ceritinib (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V]

[Ceritinib (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V] Ceritinib (nicht kleinzelliges Lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-32 [Ceritinib (non-small cell lung cancer) – benefit assessment according to §35a Social Code Book V] Ceritinib (nicht kleinzelliges Lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-32 [Ceritinib (non-small cell lung cancer) – benefit assessment (...) -small cell lung cancer) – benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 552. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pyrimidines; Sulfones; ceritinib Language Published German Country of organisation Germany English summary There is no English language summary available. Address

Health Technology Assessment (HTA) Database.2018

178. [Atezolizumab (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V]

[Atezolizumab (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V] Atezolizumab (nicht kleinzelliges lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-50 [Atezolizumab (non-small cell lung cancer) – benefit assessment according to §35a Social Code Book V] Atezolizumab (nicht kleinzelliges lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-50 [Atezolizumab (non-small cell lung cancer) – benefit (...) . [Atezolizumab (non-small cell lung cancer) – benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 576. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; atezolizumab Language Published German Country of organisation Germany English summary There is no English language summary

Health Technology Assessment (HTA) Database.2018

179. [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19]

[Alectinib (non-small-cell lung cancer) - addendum to commission A17-19] Alectinib (nicht kleinzelliges lungenkarzinom): addendum zum auftrag A17-19; auftrag A17-44 [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19] Alectinib (nicht kleinzelliges lungenkarzinom): addendum zum auftrag A17-19; auftrag A17-44 [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Alectinib (nicht kleinzelliges lungenkarzinom): addendum zum auftrag A17-19; auftrag A17-44. [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

Health Technology Assessment (HTA) Database.2018

180. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial 29129443 2017 12 15 2018 02 07 1474-5488 18 12 2017 Dec The Lancet. Oncology Lancet Oncol. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. 1610-1623 S1470-2045(17)30691-5 10.1016/S1470-2045(17)30691-5 Adjuvant (...) chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance

EvidenceUpdates2018